A Phase III, randomized study to evaluate the immunogenicity and safety of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in HIV-positive adults
Keywords: CD, cluster of differentiation; HI, haemagglutination inhibition; HIV, human immunodeficiency virus; CHMP, Committee for Medicinal Products for Human Use; AE, adverse event; SAE, serious adverse event; GMR, geometric mean ratio; GMT, geometric mean titre;